Zogenix (ZGNX) Zohydro ER Fails to Win FDA Panel Backing
- Buffett's Berkshire Hathaway Discloses ~$4.5B Stake in Phillips 66 (PSX)
- Wall St. set to open lower as September rate hike back in focus
- SunTrust Robinson Humphrey Upgrades Twitter, Inc. (TWTR) to Buy
- Amicus Therapeutics (FOLD) to Acquire Scioderm in ~$950M Deal
- Planet Fitness (PLNT) Scores 'Perfect 10' on Wall Street
Zogenix (Nasdaq: ZGNX) Zohydro ER fails to win FDA panel backing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novogen Ltd. (NVGN) Completes Strategic Review; Will Begin Interviewing CEO Candidates in Oct.
- St. Jude Medical (STJ) Announces Presentation of Positive FAME Data at ESC Congress 2015
- St. Jude Medical (STJ) Announces LEADLESS II Met Primary Endpoints
Create E-mail Alert Related CategoriesCorporate News, FDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!